On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
MondayAug 30, 2021 9:30 am

DGE’s 2nd Clinical Trial Agreements Conference to Negotiate Budgetary Restraints, Reduce Risks, and More in an Evolving Landscape

Date: September 16-17, 2021 Online Livestream Event – Locations will vary Dynamic Global Events (“DGE”) invites biopharma and medical device industry professionals to join them online September 16-17, 2021, for the 2nd Clinical Trial Agreements Conference. DGE’s first event was held online earlier this year and was focused greatly on the COVID-19 pandemic, the confidentiality of subject data, and the increased use of telemedicine, among other topics. The first event helped industry professionals determine what needed to be considered before entering into a clinical trial agreement. This conference features a distinguished speaking faculty ready to offer the strategies and best…

Continue Reading

MondayAug 30, 2021 9:30 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically covers the psychedelic renaissance and digs deeper into what has happened to the psychedelic industry from 2017 to 2020. The two-part series captures key moments in the history of the psychedelic sector, as well as providing a brief outline of  those events and the state…

Continue Reading

MondayAug 30, 2021 9:30 am

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Leveraging Data to Offer Patients, Drug Manufacturers, Researchers, Better Outcomes

Avricore Health recently announced that screening had begun at 15 select Shoppers Drug Mart Pharmacies The company intends to expand its rapid diagnostics to other parts of Canada, as well as the US, UK, and EU Avricore aims to use diagnostics to generate data that it can then use to make better decisions and create outcomes  It hopes to be a tremendous contributor to the critical data pool that is going to make medicines cheaper, more effective, and get to patients quicker When Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) signed a master agreement with Shoppers Drug Mart Inc., Canada’s leading…

Continue Reading

MondayAug 30, 2021 9:30 am

FinovateFall 2021, A Fintech Seminar To Be Held In The World’s Financial Capital

Date: September 13-15, 2021 Venue-The Marriott Marquis Times Square, New York- Virtual only access also available On September 13-15, 2021, the FinovateFall is being held at The Marriott Marquis Times Square, New York. Organizations, financial institutions, fintech industry leaders, and finance influencers are invited to attend the FinovateFall 2021, an event that can also be accessed virtually. The event will be attended by global influencers and thinkers of the finance arena who will share their valuable insights and strategies on the latest global trends. FinovateFall offers a robust platform for the fintech fraternity to establish connections and derive ideas to…

Continue Reading

MondayAug 30, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin…

Continue Reading

MondayAug 30, 2021 8:00 am

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), Committed to Fighting Global Warming Through Carbon-Free Ammonia Production

Blue and green hydrogen are the two types of hydrogen fuel types being examined for primary use – blue is less expensive but has the potential for higher greenhouse gas production, green hydrogen uses renewable energy sources like solar and wind power and creates a cleaner fuel Toyota Motor Corp. has manufactured one of the first hydrogen fuel cell-powered vehicles (Mirai), but there are only a handful of refilling stations available in Britain and three in Australia Global green ammonia market size is expected to record a CAGR growth rate of 54% from 2020 to 2025.  When combusted correctly, carbon-free…

Continue Reading

MondayAug 30, 2021 5:55 am

DSG Global Inc. (DSGT), IMC Expand EV Line, Strengthen Position in Growing Market

Company is beginning to deliver vehicles on a grander scale IMC anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year With each step forward, Imperium is seeing its dealer-candidate network of future dealers expand DSG Global (OTCQB: DSGT) and its automotive division, Imperium Motor Corp. (“IMC”), are taking significant steps forward as they strengthen their position in the growing market for smart new-energy vehicles. Imperium is working with two partners, Skywell Auto and Jonway Automotive Group, to offer 26 EV models for sale at both DSGT California facilities: the Fairfield Experience Center and…

Continue Reading

FridayAug 27, 2021 1:28 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder…

Continue Reading

FridayAug 27, 2021 1:14 pm

AmpliTech Group Inc. (NASDAQ: AMPG) Poised for Anticipated Growth in RF Communications Tech Component Market

Radio frequency (“RF”) technology designer and developer AmpliTech Group is leveraging this year’s Nasdaq uplisting and Russell Microcap Index placement to increase its market visibility AmpliTech builds and markets communications technology products for the satellite communications, space, telecommunications (5G/6G) and military defense markets  Markets analysts forecast continued growth over the next five years in the RF component sector, with a CAGR of 13 percent in the multi-billion-dollar sector AmpliTech reported a 2021 Q2 55% YOY revenue increase A recent follow-on order from an existing global defense and aerospace customer evidences AmpliTech’s growth potential as it continues to build revenues and…

Continue Reading

FridayAug 27, 2021 1:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery

Lexaria Bioscience Corp. (NASDAQ: LEXX) on July 22 announced it had met three primary objectives in its investigation of antiviral drug conversion process outcomes as the drugs are processed with its patented DehydraTECH(TM). “The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVID-19, HIV/AIDS, or other infectious disease-causing viruses, according to the company. The ultimate aim is to form partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics,” reads a recent…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered